Derek D Satre1, Alexandra N Anderson2, Amy S Leibowitz2, Tory Levine-Hall2, Sally Slome3, Jason Flamm4, C Bradley Hare5, Jennifer McNeely6, Constance M Weisner7, Michael A Horberg8, Paul Volberding9, Michael J Silverberg2. 1. Department of Psychiatry, Weill Institute for Neurosciences, University of California, San Francisco, 401 Parnassus Avenue, Box 0984, San Francisco, CA 94143, United States of America; Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612, United States of America. Electronic address: derek.satre@ucsf.edu. 2. Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612, United States of America. 3. Kasier Permanente Oakland Medical Center, 3801 Howe St, Oakland, CA 94611, United States of America. 4. Kaiser Permanente Sacramento Medical Center, 2025 Morse Ave, Sacramento, CA 95825, United States of America. 5. Kaiser Permanente San Francisco Medical Center, 2238 Geary Blvd, San Francisco, CA 94115, United States of America. 6. New York University School of Medicine, 550 1st Ave., New York, NY 10016, United States of America. 7. Department of Psychiatry, Weill Institute for Neurosciences, University of California, San Francisco, 401 Parnassus Avenue, Box 0984, San Francisco, CA 94143, United States of America; Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612, United States of America. 8. Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, 2101 East Jefferson, Rockville, MD 20852, United States of America. 9. AIDS Research Institute, University of California San Francisco, San Francisco, CA, 94158, United States of America.
Abstract
BACKGROUND: Substance use disorders (SUDs) and psychiatric disorders are common among people with HIV (PWH) and lead to poor outcomes. Yet these conditions often go unrecognized and untreated in primary care. METHODS: The Promoting Access to Care Engagement (PACE) trial currently in process examines the impact of self-administered electronic screening for SUD risk, depression and anxiety in three large Kaiser Permanente Northern California primary care clinics serving over 5000 PWH. Screening uses validated measures (Tobacco, Alcohol, Prescription medication, and other Substance use [TAPS]; and the Adult Outcomes Questionnaire [AOQ], which includes the Patient Health Questionnaire [PHQ-9] and Generalized Anxiety Disorder [GAD-2]) delivered via three modalities (secure messaging, tablets in waiting rooms, and desktop computers in exam rooms). Results are integrated automatically into the electronic health record. Based on screening results and physician referrals, behavioral health specialists embedded in primary care initiate motivational interviewing- and cognitive behavioral therapy-based brief treatment and link patients to addiction and psychiatry clinics as needed. Analyses examine implementation (screening and treatment rates) and effectiveness (SUD, depression and anxiety symptoms; HIV viral control) outcomes using a stepped-wedge design, with a 12-month intervention phase implemented sequentially in the clinics, and a 24-month usual care period prior to implementation in each clinic functioning as sequential observational phases for comparison. We also evaluate screening and treatment costs and implementation barriers and facilitators. DISCUSSION: The study examines innovative, technology-facilitated strategies for improving assessment and treatment in primary care. Results may help to inform substance use, mental health, and HIV services. TRIAL REGISTRATION: NCT03217058.
BACKGROUND: Substance use disorders (SUDs) and psychiatric disorders are common among people with HIV (PWH) and lead to poor outcomes. Yet these conditions often go unrecognized and untreated in primary care. METHODS: The Promoting Access to Care Engagement (PACE) trial currently in process examines the impact of self-administered electronic screening for SUD risk, depression and anxiety in three large Kaiser Permanente Northern California primary care clinics serving over 5000 PWH. Screening uses validated measures (Tobacco, Alcohol, Prescription medication, and other Substance use [TAPS]; and the Adult Outcomes Questionnaire [AOQ], which includes the Patient Health Questionnaire [PHQ-9] and Generalized Anxiety Disorder [GAD-2]) delivered via three modalities (secure messaging, tablets in waiting rooms, and desktop computers in exam rooms). Results are integrated automatically into the electronic health record. Based on screening results and physician referrals, behavioral health specialists embedded in primary care initiate motivational interviewing- and cognitive behavioral therapy-based brief treatment and link patients to addiction and psychiatry clinics as needed. Analyses examine implementation (screening and treatment rates) and effectiveness (SUD, depression and anxiety symptoms; HIV viral control) outcomes using a stepped-wedge design, with a 12-month intervention phase implemented sequentially in the clinics, and a 24-month usual care period prior to implementation in each clinic functioning as sequential observational phases for comparison. We also evaluate screening and treatment costs and implementation barriers and facilitators. DISCUSSION: The study examines innovative, technology-facilitated strategies for improving assessment and treatment in primary care. Results may help to inform substance use, mental health, and HIV services. TRIAL REGISTRATION: NCT03217058.
Authors: P Roux; J Cohen; C Lascoux-Combe; P Sogni; M Winnock; D Salmon-Ceron; B Spire; F Dabis; M P Carrieri Journal: Drug Alcohol Depend Date: 2011-01-15 Impact factor: 4.492
Authors: Diana Nurutdinova; Timothy Chrusciel; Angelique Zeringue; Jeffrey F Scherrer; Ziyad Al-Aly; Jay R McDonald; Edgar T Overton Journal: AIDS Date: 2012-01-14 Impact factor: 4.177
Authors: Jonathan E Volk; Julia L Marcus; Tony Phengrasamy; Derek Blechinger; Dong Phuong Nguyen; Stephen Follansbee; C Bradley Hare Journal: Clin Infect Dis Date: 2015-09-01 Impact factor: 9.079
Authors: Amy C Justice; Matthew S Freiberg; Russ Tracy; Lew Kuller; Janet P Tate; Matthew Bidwell Goetz; David A Fiellin; Gary J Vanasse; Adeel A Butt; Maria C Rodriguez-Barradas; Cynthia Gibert; Kris Ann Oursler; Steven G Deeks; Kendall Bryant Journal: Clin Infect Dis Date: 2012-02-15 Impact factor: 9.079
Authors: Niteesh K Choudhry; William H Shrank; Raisa L Levin; Joy L Lee; Saira A Jan; M Alan Brookhart; Daniel H Solomon Journal: Am J Manag Care Date: 2009-07 Impact factor: 2.229
Authors: Michelle Grunauer; David Schrock; Eric Fabara; Gabriela Jimenez; Aimee Miller; Zongshan Lai; Amy Kilbourne; Melvin G McInnis Journal: Int J Family Med Date: 2014-02-17
Authors: Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre Journal: Drug Alcohol Depend Date: 2021-09-28 Impact factor: 4.492
Authors: Alexandra N Lea; Andrea Altschuler; Amy S Leibowitz; Tory Levine-Hall; Jennifer McNeely; Michael J Silverberg; Derek D Satre Journal: Addict Sci Clin Pract Date: 2022-02-09
Authors: Nneka Emenyonu; Allen Kekibiina; Sarah Woolf-King; Catherine Kyampire; Robin Fatch; Carol Dawson-Rose; Winnie Muyindike; Judith Hahn Journal: JMIR Form Res Date: 2022-09-01
Authors: Heidi M Munger Clary; Beverly M Snively; Umit Topaloglu; Pamela Duncan; James Kimball; Halley Alexander; Gretchen A Brenes Journal: JAMIA Open Date: 2022-10-12
Authors: Borsika A Rabin; Julie Cakici; Caitlin A Golden; Paul A Estabrooks; Russell E Glasgow; Bridget Gaglio Journal: Implement Sci Date: 2022-09-24 Impact factor: 7.960